Race Oncology strengthens bisantrene IP with new patents, capital injection

Race Oncology has filed three new patent applications covering bisantrene’s isomeric forms, pharmaceutical compositions for intravenous administration, and high-purity manufacturing processes. These patents are considered crucial for protecting the active (E,E)-bisantrene isomer, which has been shown to be the most potent anticancer agent among its three photoisomers. The company emphasizes that composition of matter patents are highly valuable in the pharmaceutical industry, providing a 20-year protection period and potential five-year extensions, preventing generic competition and ensuring product exclusivity.

This strategic move comes as the company also issued 31,449 new ordinary fully paid shares on September 18, 2025, from the exercise of RACAAA options at AUD 1.25 per share, adding AUD 39,311.25 to its cash reserves. Following this issuance, Race Oncology’s total quoted securities stand at 173,834,064 ordinary fully paid shares. The unquoted RACAAA options, expiring May 29, 2026, with an exercise price of AUD 1.25, now total 19,750,440.

The strengthened IP around bisantrene is particularly significant for RC110, Race Oncology’s bisantrene formulation, which has shown a 40% overall response rate in Phase II trials for refractory/relapsed acute myeloid leukemia. This robust IP position aims to attract potential pharma partners, enabling a potential Phase 3 trial for RC110 and supporting the broader RC220 cardioprotection program.